Policy & Regulation
A 17-page report was cut to 6 pages, with fatal adverse reactions deleted Alleged outside lobbying and inadequate follow-up also come under scrutiny

The Ministry of Food and Drug Safety (MFDS) approved Genexel’s clinical trial plan for a COVID-19 treatment without detecting that its nonclinical efficacy report had been falsified.
At an Oct. 13 audit of the MFDS by the National Assembly Health and Welfare Committee, lawmakers focused on inadequate review and allegations of outside lobbying in the approval process for Genexel’s clinical trial plan. MFDS Commissioner Oh Yu-kyoung acknowledged shortcomings in the review process but repeated a general response that policy research was underway to strengthen verification of submitted materials and post-approval penalties.
Genexel applied for approval of a clinical trial plan for a COVID-19 treatment on Sept. 23, 2021. The nonclinical efficacy study report prepared by the Industry-Academic Cooperation Foundation at Jeonbuk National University was originally 17 pages, but the document ultimately submitted to the MFDS had been cut to 6 pages.
Records of fatal adverse reactions, including hamsters vomiting blood and dying, as well as bleeding and edema in lung tissue, and the researchers’ negative overall assessment had been deleted in their entirety. Although a key indicator for assessing safety before a drug is first administered to humans had been artificially sanitized, the MFDS approved the Phase 2/3 trial plan on Oct. 26, 2021, based on the falsified 6-page summary.
Questions were also raised about whether the review process followed normal procedures. On Sept. 30, 2021, the MFDS notified Genexel of more than 10 requests for additional information, comprising as many as 30 specific items. Critics said the extensive requests amounted to excessive guidance, with the MFDS effectively redrawing the plan, including the number of trial participants, dosing period and evaluation measures.
During this process, a lobbying call from the political sphere was relayed to working-level staff through the commissioner’s office on Oct. 12, 2021. Genexel voluntarily withdrew its Indian clinical trial data but pressed ahead with the falsified domestic nonclinical data and obtained approval after addressing the requests for additional information.
Regulatory gaps also came under scrutiny. Under the current Pharmaceutical Affairs Act, nonclinical testing institutions that conduct toxicity studies (GLP) are subject to strict designation and post-approval oversight, but efficacy studies demonstrating a drug’s effect can be accepted in clinical reviews even when conducted by non-designated institutions such as universities. Critics said the MFDS has few legal means to revoke a designation or impose meaningful sanctions when a non-designated institution submits false data, as in the Genexel case.
Although Commissioner Oh clearly became aware of the data falsification through a court ruling in January 2025, the MFDS had not completed an on-site inspection of the testing institution or subsequent administrative action by the time of this audit.
Post-trial safety monitoring of patients who received the drug was also inadequate. The MFDS said it had belatedly surveyed 93 trial participants around the time of the audit, but had been unable to reach 22 of them and had left only text messages.
Records showed that there had not been a single report in the 7 years since the MFDS’s rules for managing employees’ contact with outside parties were established in 2019. The MFDS said it would commission policy research in response to the incident.

Biobook Team
biobookmedia@biobook.co.kr
The ‘Valley of Death’ for Infectious Disease Treatments: Cross-Agency Coordination Is Key

Mounjaro Costs 59,000 Won in Japan, 300,000 Won in Korea, Sparking Price Debate

SME Ministry aims to develop 20 AI startups valued at 1 trillion won by 2030

MFDS to Commission Domestic Production of 3 Essential Cancer and Antibiotic Drugs, Supply Expected This Year

Up to 6 Bottles of Obesity Drugs Purchased Abroad Allowed Into Korea Starting Tomorrow

‘Public Health Care AI Highway’ Opens, Cutting Referral Form Drafting From 10 Minutes to 1